SF1670
Based on 21 publication(s) in Google Scholar
SF1670 is a potent and specific phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor.
For research use only. We do not sell to patients.
- Purity: 98.57%
- CAS No.: 345630-40-2
- Formula: C19H17NO3
- Molecular Weight:307.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Phosphatase Inhibitor Library
HY-L081
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Antidepressant Compound Library
HY-L108
-
Pain-Related Compound Library
HY-L139
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) SF1670
More- Autophagy. 2021 Dec;17(12):4159-4181. [Abstract]
- J Exp Clin Cancer Res. 2024 May 11;43(1):140. [Abstract]
- Cell Death Dis. 2020 Aug 3;11(8):646. [Abstract]
- Cell Death Dis. 2019 Mar 13;10(3):248. [Abstract]
- Acta Pharmacol Sin. 2025 Apr;46(4):1045-1057. [Abstract]
- Oncogene. 2020 Feb;39(8):1739-1755. [Abstract]
- Br J Cancer. 2024 Sep;131(5):944-953. [Abstract]
- Biochem Pharmacol. 2020 Jan;171:113674. [Abstract]
- Drug Deliv Transl Res. 2025 Oct 29. [Abstract]
- Front Pharmacol. 2022 May 16;13:848957. [Abstract]
- Mol Pharm. 2025 Jul 7;22(7):3935-3948. [Abstract]
- FASEB J. 2023 Aug;37(8):e23083. [Abstract]
- Mediators Inflamm. 2023 May 26:2023:9340499. [Abstract]
- Exp Cell Res. 2021 Nov 15;408(2):112864. [Abstract]
- Mol Med Rep. 2021 Nov;24(5):766. [Abstract]
- Mol Med Rep. 2018 Jul;18(1):349-357. [Abstract]
- Med Gas Res. 2025 Sep 1;15(3):374-382. [Abstract]
- Int J Clin Exp Med. 2019;12(7):8992-8998.
- Int J Clin Exp Med. 2019;12(7):8739-8745.
- Mater Express. 1045-1050, 2021.
- Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):3080-3087. [Abstract]
Customer Validation & Images
-
WB
Biological Activity
PTEN[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| T-cell | CC50 |
3.5 μM
Compound: 65
|
Cytotoxicity measured against human T-cells
Cytotoxicity measured against human T-cells
|
[PMID: 11356112] |
| T-cell | IC50 |
0.1 μM
Compound: 65
|
In vitro inhibition of human T-cell proliferation
In vitro inhibition of human T-cell proliferation
|
[PMID: 11356112] |
SF1670 is a specific PTEN inhibitor with prolonged intracellular retention in neutrophils. SF1670 enhances PtdIns(3,4,5)P3 signaling in transplanted neutrophils. SF1670 also elevates Akt phosphorylation in murine cells. Consistent with the enhanced Akt phosphorylation, pretreatment with SF1670 also significantly augments PtdIns(3,4,5)P3 level in mouse neutrophils. SF1670-induced Akt hyperactivation is abolished in PTEN-null neutrophils, further demonstrating that this effect is mediated by specific inhibition of PTEN activity. At 500 nM fMLP stimulation, SF1670 (500 nM)–pretreated neutrophils show nearly 70% higher (maximal) superoxide production than untreated neutrophils[1]. HCT116 cells are pre-treated with the PTEN inhibitor SF1670 (2 μM) for 24 h (untreated HCT116 cells served as control); treated cells are subsequently plated under non-adherent conditions with added MET (60 μM), Lun (2 μM), or Gen (2 μM). SF1670 binds to the PTEN active site, resulting in elevated phosphatidylinositol (3,4,5) triphosphate signaling[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss albino male mice (bodyweight 25-30 g)[1]
-
Dosage:3 mg/kg
-
Administration:Treatment with i.p.
-
Result:Lead to attenuation of cerebral I/R-induced increase in thiobarbituric acid reactive substances (TBARS).
Chemical Information
-
CAS No. 345630-40-2
-
Appearance Solid
-
Molecular Weight 307.34
-
Formula C19H17NO3
-
Color Pink to red
-
SMILES
CC(C)(C)C(NC(C=C1C2=O)=CC=C1C3=C(C2=O)C=CC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
PRDX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. [Abstract]2021 Dec;17(12):4159-4181. PMID: 33749526 -
J Exp Clin Cancer Res
Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells. [Abstract]2024 May 11;43(1):140. PMID: 38730468 -
Cell Death Dis
LncRNA SNHG14 promotes hepatocellular carcinoma progression via H3K27 acetylation activated PABPC1 by PTEN signaling. [Abstract]2020 Aug 3;11(8):646. PMID: 32811821 -
Cell Death Dis
The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway. [Abstract]2019 Mar 13;10(3):248. PMID: 30867411 -
Acta Pharmacol Sin
Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis. [Abstract]2025 Apr;46(4):1045-1057. PMID: 39627385 -
Oncogene
2020 Feb;39(8):1739-1755. PMID: 31740781 -
Br J Cancer
Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism. [Abstract]2024 Sep;131(5):944-953. PMID: 38987365 -
Biochem Pharmacol
Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells. [Abstract]2020 Jan;171:113674. PMID: 31634455 -
Drug Deliv Transl Res
Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs. [Abstract]2025 Oct 29. PMID: 41160380 -
Front Pharmacol
Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1. [Abstract]2022 May 16;13:848957. PMID: 35652039 -
Mol Pharm
Macropinocytosis and Fast Endophilin-Mediated Endocytosis Mediate Absorption of Garlic Chive-Derived Vesicle-like Nanoparticles in Human Intestinal Epithelial Cells. [Abstract]2025 Jul 7;22(7):3935-3948. PMID: 40409744 -
FASEB J
Nur77 is involved in the regulation of obesity-related lower muscle mass by promoting Pten degradation. [Abstract]2023 Aug;37(8):e23083. PMID: 37402127 -
Mediators Inflamm
GATA6-AS1 via Sponging miR-543 to Regulate PTEN/AKT Signaling Axis Suppresses Cell Proliferation and Migration in Gastric Cancer. [Abstract]2023 May 26:2023:9340499. PMID: 37273453 -
Exp Cell Res
Selenomethionine protects oxidative-stress-damaged bone-marrow-derived mesenchymal stem cells via an antioxidant effect and the PTEN/PI3K/AKT pathway. [Abstract]2021 Nov 15;408(2):112864. PMID: 34626586 -
Mol Med Rep
Regulation of the PTEN/PI3K/AKT pathway in RCC using the active compounds of natural products in vitro. [Abstract]2021 Nov;24(5):766. PMID: 34490473 -
Mol Med Rep
Overexpression of Annexin A1 protects against benzo[a]pyrene‑induced bronchial epithelium injury. [Abstract]2018 Jul;18(1):349-357. PMID: 29749523
SF1670 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2018 Jul;18(1):349-357. [Abstract]
The Western blotting data indicates that the enhanced expression of PTEN and FAK is decreased by SF1670. And the decreased expression of p-PI3K/p-Akt is augmented by SF1670.
-
Med Gas Res
Dietary addition of magnesium hydride nanoparticles: a breakthrough in combating high-fat diet-induced chronic kidney disease. [Abstract]2025 Sep 1;15(3):374-382. PMID: 40251018 -
-
-
-
Eur Rev Med Pharmacol Sci
Over-expression of DJ-1 attenuates effects of curcumin on colorectal cancer cell proliferation and apoptosis. [Abstract]2019 Apr;23(7):3080-3087. PMID: 31002157
Solvent & Solubility
DMSO : ≥ 50 mg/mL (162.69 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li Y, et al. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood. 2011 Jun 16;117(24):6702-13. [Content Brief]
[2]. Montales MT, et al. Metformin and soybean-derived bioactive molecules attenuate the expansion of stem cell-like epithelial subpopulation and confer apoptotic sensitivity in human colon cancer cells. Genes Nutr. 2015 Nov;10(6):49. [Content Brief]
[3]. Amarjot Kaur Grewal, et al. Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia-reperfusion-induced injury in mice. J Pharm Pharmacol. 2019 Jun;71(6):956-970. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2537 mL | 16.2686 mL | 32.5373 mL | 81.3431 mL |
| 5 mM | 0.6507 mL | 3.2537 mL | 6.5075 mL | 16.2686 mL | |
| 10 mM | 0.3254 mL | 1.6269 mL | 3.2537 mL | 8.1343 mL | |
| 15 mM | 0.2169 mL | 1.0846 mL | 2.1692 mL | 5.4229 mL | |
| 20 mM | 0.1627 mL | 0.8134 mL | 1.6269 mL | 4.0672 mL | |
| 25 mM | 0.1301 mL | 0.6507 mL | 1.3015 mL | 3.2537 mL | |
| 30 mM | 0.1085 mL | 0.5423 mL | 1.0846 mL | 2.7114 mL | |
| 40 mM | 0.0813 mL | 0.4067 mL | 0.8134 mL | 2.0336 mL | |
| 50 mM | 0.0651 mL | 0.3254 mL | 0.6507 mL | 1.6269 mL | |
| 60 mM | 0.0542 mL | 0.2711 mL | 0.5423 mL | 1.3557 mL | |
| 80 mM | 0.0407 mL | 0.2034 mL | 0.4067 mL | 1.0168 mL | |
| 100 mM | 0.0325 mL | 0.1627 mL | 0.3254 mL | 0.8134 mL |
Powered by Bioz